A Study of 9-valent Extraintestinal Pathogenic Escherichia Coli Vaccine (ExPEC9V) and High-dose Quadrivalent Influenza Vaccine, With and Without Co-administration, in Adults Aged 65 Years or Older

Conditions: Invasive Extraintestinal Pathogenic Escherichia Coli Disease (IED) Prevention Interventions: Biological: ExPEC9V; Biological: Placebo; Biological: HD quadrivalent influenza vaccine Sponsors: Janssen Research& Development, LLC Recruiting

https://clinicaltrials.gov/study/NCT06134804

Source: ClinicalTrials.gov - November 16, 2023 Category: Research Source Type: clinical trials